Sigma Planning Corp’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Sigma Planning Corp’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,001	Closed	-$20K	–	1374
2022 Q4	$20K	Hold	1,001	–	–	﹤0.01%	1238
2022 Q3	$18K	Hold	1,001	–	–	﹤0.01%	1246
2022 Q2	$22K	Hold	1,001	–	–	﹤0.01%	1271
2022 Q1	$28K	Buy	1,001 +25	+3%	+$910	﹤0.01%	1347
2021 Q4	$44K	Buy	976 +367	+60%	+$24.7K	﹤0.01%	1360
2021 Q3	$51K	Sell	609 -24	-4%	-$1.99K	﹤0.01%	1346
2021 Q2	$60K	Buy	+633	New	+$75.1K	﹤0.01%	1390

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Sigma Planning Corp's ONCT Position: Q1 2023 in Review

Sigma Planning Corp sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2023, closing a stake of 1,001 shares — an estimated $20K sold.

Sigma Planning Corp first reported a position in ONCT in Q2 2021 and held it in 7 quarters. The position peaked at $60K in Q2 2021. 54 funds tracked by Wall St. Rank hold ONCT as of Q1 2023.

Sigma Planning Corp reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Sigma Planning Corp sold 1,001 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $20K.
Sigma Planning Corp first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
Sigma Planning Corp's Oncternal Therapeutics, Inc. Common Stock position peaked at $60K in Q2 2021.
54 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Sigma Planning Corp's 13F filing for Q1 2023, filed 8 May 2023.